EP2099295A4 - Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids - Google Patents

Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids

Info

Publication number
EP2099295A4
EP2099295A4 EP07862162A EP07862162A EP2099295A4 EP 2099295 A4 EP2099295 A4 EP 2099295A4 EP 07862162 A EP07862162 A EP 07862162A EP 07862162 A EP07862162 A EP 07862162A EP 2099295 A4 EP2099295 A4 EP 2099295A4
Authority
EP
European Patent Office
Prior art keywords
prophlyaxis
omega
treatment
fatty acids
atrial fibrillation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07862162A
Other languages
German (de)
French (fr)
Other versions
EP2099295A1 (en
Inventor
Robert A Shalwitz
Roelof M L Rongen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reliant Pharmaceuticals Inc
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of EP2099295A1 publication Critical patent/EP2099295A1/en
Publication of EP2099295A4 publication Critical patent/EP2099295A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
EP07862162A 2006-11-22 2007-11-21 Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids Withdrawn EP2099295A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86049506P 2006-11-22 2006-11-22
PCT/US2007/024283 WO2008066745A1 (en) 2006-11-22 2007-11-21 Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids

Publications (2)

Publication Number Publication Date
EP2099295A1 EP2099295A1 (en) 2009-09-16
EP2099295A4 true EP2099295A4 (en) 2010-02-24

Family

ID=39468221

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07862162A Withdrawn EP2099295A4 (en) 2006-11-22 2007-11-21 Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids

Country Status (3)

Country Link
EP (1) EP2099295A4 (en)
JP (1) JP2010510313A (en)
WO (1) WO2008066745A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20012384A1 (en) 2001-11-12 2003-05-12 Quatex Nv USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS
US8974828B2 (en) 2009-03-18 2015-03-10 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CN103476405A (en) * 2011-02-07 2013-12-25 持田制药株式会社 Therapeutic agent for diastolic congestive heart failure
EP3411030A4 (en) 2016-02-01 2019-09-04 InCarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
KR20200003199A (en) 2017-05-10 2020-01-08 인카다 테라퓨틱스, 인크. Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary administration
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
RU2722052C1 (en) * 2019-12-30 2020-05-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for determining the risk of developing atrial fibrillation in patients with ischemic heart disease, taking omega-3 polyunsaturated fatty acids in coronary artery bypass grafting

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044028A1 (en) * 2001-03-30 2004-03-04 Obukowicz Mark G. Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
ITMI20022511A1 (en) * 2002-11-26 2004-05-27 Victorix Assets Ltd USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.
CA2523746A1 (en) 2003-04-24 2004-11-25 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BISCIONE FRANCESCO ET AL: "[Effect of omega-3 fatty acids on the prevention of atrial arrhythmias]", ITALIAN HEART JOURNAL. SUPPLEMENT : OFFICIAL JOURNAL OF THE ITALIAN FEDERATION OF CARDIOLOGY JAN 2005, vol. 6, no. 1, January 2005 (2005-01-01), pages 53 - 59, XP009127037, ISSN: 1129-4728 *
KATAN MARTIJN B ET AL: "Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: An 18-month controlled study", JOURNAL OF LIPID RESEARCH, vol. 38, no. 10, 1997, pages 2012 - 2022, XP002560498, ISSN: 0022-2275 *
See also references of WO2008066745A1 *

Also Published As

Publication number Publication date
WO2008066745A9 (en) 2008-08-28
WO2008066745A1 (en) 2008-06-05
EP2099295A1 (en) 2009-09-16
JP2010510313A (en) 2010-04-02

Similar Documents

Publication Publication Date Title
EP2099295A4 (en) Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids
EP1904049A4 (en) Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
ZA201003030B (en) Medium-chain length fatty acids and glycerides as nephroprotection agents
EP2136844A4 (en) Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
EP2089014A4 (en) Omega-3 fatty acids and dyslipidemic agent for reduction of apo-b levels
EP2358882A4 (en) Enzymes and methods for producing omega-3 fatty acids
EP2120920A4 (en) Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
EP2083815A4 (en) Statin and omega-3 fatty acids for reduction of apo-b levels
EP1919468A4 (en) Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
EP2083622A4 (en) Omega-3 fatty acids for reduction of lp-pla2 levels
EP2240017A4 (en) Ketone bodies and ketone body esters as blood lipid lowering agents
PL2427415T3 (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
ZA201008170B (en) Polypeptides and methods for producing triacyglycerols comprising modified fatty acids
EP1861087A4 (en) Treatment with statin and omega-3 fatty acids and a combination product thereof
EP2173699A4 (en) Production and purification of esters of polyunsaturated fatty acids
PL2214638T3 (en) Composition comprising polyunsaturated fatty acids and activated charcoal
EP2131679A4 (en) Fatty acid formulations and methods of use thereof
IL219874A0 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
HK1159604A1 (en) Hydroxybutyrate ester and medical use thereof
IL207309A0 (en) Lipases with high specificity towards short chain fatty acids and uses thereof
EP2324119A4 (en) Mutant delta5 desaturases and their use in making polyunsaturated fatty acids
EP2046957A4 (en) Fatty acid desaturases and uses thereof
SI2034999T1 (en) Dha esters and use thereof in the treatment and the prevention of cardiovascular diseases
EP2114397A4 (en) Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof
ZA200807341B (en) Fatty acid by-products and methods of using same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090618

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/06 20060101ALI20100105BHEP

Ipc: A61K 45/06 20060101ALI20100105BHEP

Ipc: A61K 31/202 20060101AFI20100105BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100122

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20090618

17Q First examination report despatched

Effective date: 20100331

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100811